In the overall multivariate analysis (Table 3), HAART use during TB treatment (p = 0.01) and CD4 lymphocyte count ≥100 cells/mm3 (p = 0.05) were associated with significantly lower mortality, while subjects with unknown baseline CD4 cell count (p<0.001) had a significantly higher mortality. The gene discussed is CD4; the disease is tuberculosis.